- **Orders received** rose by 16% to SEK 6,669 million (5,767)
- **Net sales** rose by 16% to SEK 6,123 million (5,264)
- **Profit before tax** amounted to SEK 626 million (617)
- **Net profit** amounted to SEK 457 million (444)
- **Profit per share** totalled SEK 2.24 (2.16)
- **Orders received increased organically by a good 13% during the quarter**
- **Favourable cash flow**
- **Continued positive outlook for the year**

Second quarter 2006

Orders received

The trend for orders received by the Group was highly positive during the quarter and these increased organically by a good 13.0% compared with the favourable second quarter of 2005. Adjusted for the major orders booked in Canada during the first quarter of the preceding and the current year, the organic increase in orders received amounted to 11.5% for the first six months of the year.

Orders received by Medical Systems remain strong and increased organically by 16.7% during the quarter. All of the divisions included in the business area recorded favourable growth, particularly Surgical Workplaces.

Infection Control's orders received grew organically by a good 12.9% during the quarter. The volume trend in North America and in developing markets was particularly positive.

Extended Care, which had weak volume growth at the beginning of the year, had an improvement in its orders received during the quarter. Organically, orders received increased by 5.9%, with a stable trend in North America and Western Europe.

Results

Consolidated profit before tax rose by 19.8% to SEK 364.3 million (304.2). The profit improvement is attributable to favourable growth in invoicing during the period.

Medical Systems' operating profit increased by 31.7% as a result of favourable growth in invoicing, strong price control and a good product mix. The operating margin improved by 2.4 percentage points.

Infection Control's operating profit grew by 8.2% during the period. The reduced operating margin during the period was attributable to the acquisition of La

Cahlène, which was not included in the business area in the corresponding period last year.

In Extended Care, the operating profit was at the same level as the preceding year. Results continue to be affected by the plant closure of the unit in Gloucester, which will be completed during the third quarter of the year.

The Group's cash flow continued to develop well. Operational cash flow amounted to SEK 679 million (601).

Outlook 2006

The Group's assessment of the demand for Group products remains positive. Demand in the developing markets and in North America is on a favourable and stable level, while demand in Western Europe has improved since the end of 2005. The Group's order backlog remains at a favourable level compared with the corresponding time in 2005.

Medical Systems anticipates a continued favourable volume trend for the current year as a result of the product launches conducted and the gradual build-up of the business area's market organisation that is in progress in North America and the developing markets. Earnings are expected to improve for the Cardiopulmonary Division, which had a weak trend in 2005. Several future-oriented measures were taken to secure the business area's long-term competitiveness. The market organisation in the developing markets is being successively extended, with the focus on Southeast Asia, Eastern Europe, India, China and Latin America. In Critical Care and Cardiopulmonary, product-development work is being intensified prior to planned launches in 2007. In addition, activities are being undertaken to increase competitiveness in production, with the build-up of a production unit in Turkey for Cardiopulmonary and local production of surgical equipment in China.

The volume trend for Infection Control is also expected to be favourable in most geographical regions in the current year. The changes implemented by the business area's North American operations led to distinct improvement in the sales volume. Similar to Medical Systems, investments are being made to strengthen the sales organisation in the markets outside Europe. In addition to the activities in the US, the organisation in China, Japan, India and Latin America has been strengthened. Work to enhance the efficiency of the supply organisation is progressing for both the plant and logistics structures. La Cahlène, which is included in the business area's operations from the third quarter of 2005, has now been fully integrated into the business area. La Cahlène is expected to contribute to profit before tax in an amount of approximately SEK 30 million, excluding restructuring costs amounting to about SEK 20 million.

The volume growth for the Extended Care business area is expected to be modest, but with a distinct improvement in Western Europe. The large deliveries of patient-handling equipment made to Canada in 2005 are partly compensated by a new investment program in Canada during the current year and the delivery of the alternative products to the patientlifters accumulated as a result of the FDA embargo. The new Maxi family of patient hoists will contribute to volume growth during the second half of the year. The adjustment of the production structure for patient-handling equipment will generate restructuring costs of approximately SEK 45 million for the current year. Planned savings as a result of this restructuring are expected to total SEK 50 million in 2007 and about SEK 70 million from 2008.

In conclusion, the Group anticipates favourable volume growth during the year, while an increasing number of future-oriented investments will be made in product development, production structure and the market organisation.

The Group has not changed its view regarding the earnings outlook for the year since the publication of the most recent report, except for a slight weakening in the currency situation. The weaker earnings trend within Extended Care will be offset by better development in Medical Systems, which is expected to continue for the remainder of the year.

Business area Medical Systems

Market development

Orders received per market	2006 Q 2	2005 Q 2	*Change adjusted for curr.flucs.&corp.acqs.*	2006 6 Mon	2005 6 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Western Europe	**699.0**	672.1	*3.2%*	**1,405.6**	1,322.1	*4.3%*
USA and Canada	**278.4**	264.1	*3.6%*	**618.7**	478.5	*20.0%*
Asia and Australia	**226.3**	247.1	*-8.5%*	**420.2**	445.9	*-7.8%*
Rest of the world	**323.3**	110.7	*186.1%*	**478.4**	178.3	*158.2%*
Business area total	**1,527.0**	1,294.0	*16.7%*	**2,922.9**	2,424.8	*16.5%*

The trend for orders by the business area received remained strong and rose organically by 16.7%.

In the West European markets, demand and orders received were stable. Orders received in the UK declined somewhat, while other regions, Scandinavia, Southern Europe, Benelux and the German-speaking countries, performed better than in the year-earlier period.

Orders received in North America were strong during the period, but compared with the extremely strong second quarter in 2005, the increase was more modest.

The Asia region recorded a weaker volume trend during the quarter, mainly in China and Japan, but the assessment is that demand in the region remains favourable. In other developing markets, orders received were extremely strong, particularly in Latin America and Russia.

Results

	2006 Q 2	2005 Q 2	*Change*	2006 6 Mon	2005 6 Mon	*Change*	2005 FY
Net sales, SEK million	**1,316.1**	1,185.0	*11.1%*	**2,578.2**	2,214.0	*16.4%*	5,109.2
adjusted for currency flucs.& corp.acqs			*9.7%*			*12.5%*	
Gross profit	**665.7**	574.6	*15.9%*	**1,282.3**	1,082.0	*18.5%*	2,486.3
Gross margin %	***50.6%***	*48.5%*	*2.1%*	***49.7%***	*48.9%*	*0.8%*	*48.7%*
Operating cost, SEK million	**-470.0**	-426.0	*10.3%*	**-925.7**	-819.2	*13.0%*	-1,704.9
EBITA	**197.2**	150.3	*31.2%*	**359.6**	265.4	*35.5%*	787.3
EBITA margin %	***15.0%***	*12.7%*	*2.3%*	***13.9%***	*12.0%*	*1.9%*	15.4%
EBIT	**195.7**	148.6	*31.7%*	**356.6**	262.8	*35.7%*	781.4
EBIT margin %	***14.9%***	*12.5%*	*2.4%*	***13.8%***	*11.9%*	*1.9%*	*15.3%*

Operating profit increased by 31.7%, while the operating margin rose by 2.4%. The positive earnings trend is an effect of strong growth in invoicing in all divisions. The improved gross margin is attributable to good price control, a favourable mix and improvements in the Cardiopulmonary division. The increased costs are in line with the planned investments that continue to be made in the US and the developing markets, as well as product-development measures.

Activities

Product launches
The introduction of most of the products launched in the fourth quarter of 2005 is proceeding according to plan. The Magnus surgical table secured several key orders during the start of the year, which will result in deliveries during the second half of the year.

Product development
The development projects within Critical Care that were announced earlier are progressing according to plan. The projects include the development of a new generation of anaesthesia machines (NGA), with competitive advantages in terms of clinical performance and cost structure, and the development of a new ventilator (NAVA), which is expected to be able to shorten treatment time in intensive care. In addition to this, Cardiopulmonary conducts a broad development program in terms of the division’s consumables, which will lead to product launches in 2007 and beyond.

New production structure within Cardiopulmonary
As previously announced, Cardiopulmonary is implementing extensive changes to its production structure. Simpler and personnel-intensive production will be located at the business area’s plant in Turkey, which is being constructed, while more capital-intensive production will be focused on one of the three existing units in Germany. The restructuring program is expected to be completed at the end of 2007.

Local production in China
During the next three-year period, Medical Systems intends to locate some production of surgical equipment in China. Ceiling service units will be delivered from the plant in Suzhou before the end of the year and, in the period 2007-2008, the locally produced range will be extended to include surgical lights and surgical tables.

Business area Infection Control

Market development

Orders received per market	2006 Q 2	2005 Q 2	Change adjusted for curr.flucs.&corp.acqs.	2006 6 Mon	2005 6 Mon	Change adjusted for curr.flucs.&corp.acqs.
Western Europe	**511.8**	442.3	*3.8%*	**1,042.4**	841.9	*9.4%*
USA and Canada	**398.7**	333.7	*12.2%*	**755.3**	600.6	*5.3%*
Asia and Australia	**133.3**	81.8	*57.9%*	**239.3**	208.4	*9.8%*
Rest of the world	**44.7**	34.5	*28.9%*	**105.6**	72.0	*39.9%*
Business area total	**1,088.5**	892.3	*12.9%*	**2,142.6**	1,722.9	*9.3%*

Orders received by the business area developed well during the quarter and increased organically by 12.9%.

The volume trend in Western Europe was stable, with moderate increases in the UK, Benelux and the German-speaking markets. In Southern Europe, the trend was favourable, while orders received declined somewhat in Scandinavia.

Orders received in the North American market were extremely favourable, particularly in terms of the hospital market.

In the developing markets, orders received were generally favourable for Southeast Asia, Eastern Europe, Russia and China.

Results

	2006 Q 2	2005 Q 2	Change	2006 6 Mon	2005 6 Mon	Change	2005 FY
Net sales, SEK million	**1,055.2**	855.1	*23.4%*	**1,949.2**	1,547.7	*25.9%*	3,745.1
adjusted for currency flucs.& corp.acqs			*11.1%*			*10.4%*	
Gross profit	**398.4**	329.3	*21.0%*	**747.9**	603.1	*24.0%*	1,429.2
Gross margin %	***37.8%***	*38.5%*	*-0.7%*	***38.4%***	*39.0%*	*-0.6%*	*38.2%*
Operating cost, SEK million	**-283.1**	-222.7	*27.1%*	**-552.9**	-429.5	*28.7%*	-917.8
EBITA	**119.2**	106.6	*11.8%*	**202.7**	173.6	*16.8%*	517.9
EBITA margin %	***11.3%***	*12.5%*	*-1.2%*	***10.4%***	*11.2%*	*-0.8%*	*13.8%*
EBIT	**115.3**	106.6	*8.2%*	**195.0**	173.6	*12.3%*	511.4
EBIT margin %	***10.9%***	*12.5%*	*-1.6%*	***10.0%***	*11.2%*	*-1.2%*	*13.7%*

Operating profit increased by 8.2% during the quarter, while the operating margin declined. The lower operating margin is an effect of the La Cahlène acquisition, which was integrated with the business area’s results as of the third quarter of 2005. La Cahlène, which was recently integrated into the business area, has a diluting effect on the operating margin for the current year. Excluding La Cahlène, the business area’s operating margin is comparable with the preceding year. Similar to Medical Systems, investments are being made to expand and strengthen the market organisation in several markets, including China, Japan, India and the US. Most of the period’s increases in operating expenses were also attributable to La Cahlène.

Restructuring costs for the integration of La Cahlène amounted to SEK 1.1 million for the quarter. During the quarter, SEK 4.0 million was reserved for the closure of the business area's operations in South Africa (see Activities).

Activities

Logistics project
Infection Control's logistics project, aimed at simplifying and enhancing the efficiency in administration of ordering and invoicing procedures and centralising the physical handling of products and spare parts, is proceeding according to plan. The project will be completed in 2007 and will lead to annual cost-savings of SEK 50 million.

La Cahlène
The integration of La Cahlène with Infection Controls existing organisation has essentially been completed. Sales and marketing of La Cahlène's product range are now coordinated with Infection Control's other Life Science products from a number of dedicated centres. Through the new organisation, an efficient and focused market organisation has been created, which can meet the global Life Science customers in an effective manner. The business area anticipates favourable volume growth for La Cahlène's products in the next few years through Getinge's global market presence. The closure of La Cahlène's UK plant was completed during the quarter and the restructuring costs related to this are charged to earnings in an amount of SEK 1.1 million.

Establishing in China
The plans to also produce washer disinfectors this year, in addition to the sterilisers that have been produced in China since the preceding year, are proceeding according to plan. Simultaneous with the build-up of competitive production, the market organisation in China is also being extended.

Outsourcing
As announced earlier, the UK NHS (National Health Service) plans to establish a number of supercentres, which will provide public-sector hospitals with sterile instruments on an outsourcing basis. About 20 centres are currently under development. Infection Control is considered to have favourable opportunities to secure a large number of these projects. Potential orders from these projects are not expected to impact the current year.

New low-temperature disinfector
During the quarter, Infection Control launched a low-temperature disinfector for "point of care" use. The disinfection process is based on peracetic acid and handling is simple and safe. The processing time for a disinfecting cycle is approximately 20 minutes, which is highly competitive and an important decision parameter for potential customers. Initially, the product will be marketed in Europe, but the ambition is also to market it in the US, with the relevant FDA approval.

South Africa operations discontinued
Since 1995, Getinge has had its own operations in South Africa, which it gained through the acquisition of Anzy Sterilizer (Pty) Ltd. The operations, which comprise production and sales, have generated losses for a long time, which is why the business area decided to discontinue the business and to use a local distributor with nationwide coverage to manage this market in future. In the future, products for sale in South Africa will be delivered form existing plants in Europe. The cost of discontinuing the operation amounts to about SEK 4 million, which was charged to the earnings for the quarter.

Business area Extended Care

Market development

Orders received per market	2006 Q 2	2005 Q 2	Change adjusted for curr.flucs.&corp.acqs.	2006 6 Mon	2005 6 Mon	Change adjusted for curr.flucs.&corp.acqs.
Western Europe	**457.8**	427.9	*6.5%*	**942.0**	870.2	*6.1%*
USA and Canada	**241.9**	221.2	*5.6%*	**583.9**	663.6	*-20.3%*
Asia and Australia	**31.2**	32.0	*-2.6%*	**51.9**	53.9	*-6.2%*
Rest of the world	**5.6**	3.9	*31.8%*	**10.7**	8.3	*20.8%*
Business area total	**736.5**	685.0	*5.9%*	**1,588.5**	1,596.0	*-5.2%*

Orders received improved during the period and increased organically by 5.9%.

In the important West European market, orders received organically grew by 6.5%. In the German-speaking markets, orders received were in line with the preceding year, while all other regions recorded favourable growth, particularly Southern Europe and Scandinavia.

The volume trend in North America was stable in both Canada and the US.

Orders received in the developing markets were in line with 2005.

Results

	2006 Q 2	2005 Q 2	Change	2006 6 Mon	2005 6 Mon	Change	2005 FY
Net sales, SEK million	**773.4**	687.9	*12.4%*	**1,580.5**	1,480.3	*6.8%*	2,982.1
adjusted for currency flucs.& corp.acqs			*10.3%*			*1.5%*	
Gross profit	**350.5**	313.4	*11.8%*	**704.5**	705.7	*-0.2%*	1,396.9
Gross margin %	***45.3%***	*45.6%*	*-0.3%*	***44.6%***	*47.7%*	*-3.1%*	*46.8%*
Operating cost, SEK million	**-249.7**	-215.3	*16.0%*	**-534.7**	-427.4	*25.1%*	-891.1
EBITA	**104.6**	101.8	*2.8%*	**177.6**	285.6	*-37.8%*	521.6
EBITA margin %	***13.5%***	*14.8%*	*-1.3%*	***11.2%***	*19.3%*	*-8.1%*	*17.5%*
EBIT	**100.7**	98.1	*2.7%*	**169.8**	278.3	*-39.0%*	505.8
EBIT margin %	***13.0%***	*14.3%*	*-1.3%*	***10.7%***	*18.8%*	*-8.1%*	*17.0%*

Operating profit for the period was somewhat higher than for the year-earlier period. Gross margin improved during the period compared with the beginning of the year and is expected to have a positive trend as the production restructuring in patient handling equipment is completed during the third quarter of the year. The order backlog created in the wake of the FDA's earlier import embargo was essentially delivered during the quarter by alternative products from the other patient handling equipment plants. The higher costs for the quarter are partly attributable to expense connected with the establishment of a new organisation for Extended Care (see Activities) and the build-up of a market organisation in the US.

Activities

Restructuring of the business area's production of patient-handling equipment

As announced earlier, Extended Care is conducting a restructuring of the production structure for patient-handling equipment. The production unit in Gloucester is being discontinued and production relocated to the business area's units in Magog, Canada, and Hamont-Achel, in Belgium. The unit in Belgium will focus on the production of active hoists, while the unit in Canada will be a centre for passive hoists. The program is expected to be completed during the third quarter of the year and will lead to annual savings of about SEK 50 million in 2007 and annual savings of about SEK 70 million from 2008 onward. The restructuring costs totalling SEK 45 million were charged to the first quarter of the year.

New organisation in Extended Care

As part of the effort to increase the business area’s competitiveness and level of activity, Extended Care’s operations have been reorganised. Three divisions have been created: Products and Marketing, Supply Chain and Sales. Products and Marketing is responsible for the product area’s business range and comprises product development, product responsibility and marketing. Supply Chain is responsible for production, purchasing and logistics. Sales comprises all market companies. The primary aim of the new organisation is to increase the pace of product renewal and to improve competitiveness through better use of economies of scale in production and purchasing. A number of new managers have been recruited in an effort to put the new organisation in place, while some personnel were laid off. The cost of personnel lay-offs amounted to SEK 14 million for the quarter.

Other information

Companies acquired and divested in 2006

During the second quarter, the company LIC Audio AB, whose operations are reported separately in the Getinge Group, was divested. The company develops, sells and performs service/installation of products for sound distribution, with a focus on hearing care. Sales in 2005 were SEK 44 million. The agreed purchase price for the shares of SEK 15 million, after deduction of consolidated value, generated a capital gain of SEK 6 million for the quarter. After the end of the reporting period, the remaining 25% of the shares in the Canadian company BHM Medical Inc. were acquired at a purchase price of SEK 198 million in accordance with the original agreement. The transaction generates no change in the acquisition balance established earlier.

Share-related remuneration

In accordance with the decision by the Annual General Meeting on April 20 2006, Group management has been made an offer to acquire 900,000 call options. Group management has acquired 155,000 of the options offered. Considering the amount paid by Group management, Getinge's cost will amount to a maximum of SEK 1.5 million.

Accounting

This interim report was prepared in accordance with IAS 34 Interim Financial Reporting. The same accounting principles and methods of calculation were used in this interim report as in the most recent annual report. The report is unaudited.

Future-oriented information

This report contains future-oriented information based on the current expectations of Getinge's Group management. Although the management deems that the expectations presented by such future-oriented information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the future-oriented information due to such factors as changed conditions regarding finance, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.

Next report

The next report from the Getinge Group (third quarter 2006) will be published on 18 October 2006.

Teleconference

A teleconference will be held today at 9:00 a.m. Swedish time. To participate, please call:
from Sweden 08-505 20110, password: Getinge
from outside Sweden +44(0)20 7162 0025, password: Getinge

A recorded version of the conference will be available for five working days on the following numbers:
Sweden: +46 (0) 850520333, access code: 709694
UK: +44 (0)20 7031 4064, access code: 709694

Getinge 17 juli 2006

Johan Malmquist
President

Getinge AB
Box 69, 310 44 Getinge
Telephone +46 (0)35 15 55 00. Fax +46 (0)35 549 52
email info@getinge.com
Company reg. No. 556408-5032
www.getinge.com

Income statement

SEK million	2006 Q 2	2005 Q 2	Change	2006 6 Mon	2005 6 Mon	Change	2005 FY
Net sales	**3,147.7**	2,739.0	*14.9%*	**6,122.5**	5,264.2	*16.3%*	11,880.4
Cost of goods sold	**-1,732.4**	-1,518.7	*14.1%*	**-3,383.7**	-2,867.4	*18.0%*	-6,554.9
Gross profit	**1,415.3**	1,220.3	*16.0%*	**2,738.8**	2,396.8	*14.3%*	5,325.5
Gross margin	*45.0%*	*44.6%*	*0.4%*	*44.7%*	*45.5%*	*-0.8%*	*44.8%*
Selling expenses	**-626.6**	-546.5	*14.7%*	**-1,223.8**	-1,053.4	*16.2%*	-2,205.3
Administrative expenses	**-289.6**	-254.2	*13.9%*	**-580.6**	-494.1	*17.5%*	-1,055.5
Research & development costs [1]	**-71.3**	-65.6	*8.7%*	**-152.9**	-133.6	*14.4%*	-257.1
Other operating income and expenses	**-9.9**	-0.4	*2375.0%*	**-52.8**	0.3	*-17700.0%*	-4.8
Operating profit [2]	**417.9**	353.6	*18.2%*	**728.7**	716.0	*1.8%*	1,802.8
Operating margin	*13.3%*	*12.9%*	*0.4%*	*11.9%*	*13.6%*	*-1.7%*	*15.2%*
Financial net	**-53.6**	-49.4		**-102.8**	-98.9		-201.4
Profit before tax	**364.3**	304.2	*19.8%*	**625.9**	617.1	*1.4%*	1,601.4
Taxes	**-98.4**	-85.2		**-169.0**	-172.8		-451.7
Net profit	**265.9**	219.0	*21.4%*	**456.9**	444.3	*2.8%*	1,149.7
Attributable to:							
Parent company's shareholders	**264.9**	217.1		**452.0**	436.6		1,138.4
Minority interest	**1.0**	1.9		**4.9**	7.7		11.3
Net profit	**265.9**	219.0		**456.9**	444.3		1,149.7
Earnings per share, SEK [3]	**1.31**	1.08	*21.4%*	**2.24**	2.16	*3.5%*	5.64

1) Development costs totalling SEK 82.0 (70.2) million have been capitalised during the year, of which 50.3 (43.6) million were capitalised during the quarter.

2) Operating profit is charged with

— depr. intangibles	***-19.2***	*-11.8*		***-38.3***	*-22.0*		*-54.1*
— depr. on other fixed assets	***-62.9***	*-67.0*		***-134.0***	*-130.0*		*-274.6*
	-82.1	*-78.8*		***-172.3***	*-152.0*		*-328.7*

3) There are no dilutions

4) Due to reclassification of certain costs, some transfer have been made in the comparision from cost of goods sold to operating costs.

Quarterly results

SEK million	2004 Q 2	2004 Q 3	2004 Q 4	2005 Q 1	2005 Q 2	2005 Q 3	2005 Q 4	2006 Q 1	2006 Q 2
Net sales	2,588.1	2,332.5	3,476.6	2,525.2	2,739.0	2,727.4	3,888.8	2,974.8	3,147.7
Cost of goods sold	-1,409.5	-1,274.0	-1,981.1	-1,348.7	-1,518.7	-1,524.4	-2,163.1	-1,651.3	-1,732.4
Gross profit	1,178.6	1,058.5	1,495.5	1,176.5	1,220.3	1,203.0	1,725.7	1,323.5	1,415.3
Operating cost	-771.8	-753.7	-815.0	-814.1	-866.7	-856.4	-985.5	-1,012.7	-997.4
Operating profit	406.8	304.8	680.5	362.4	353.6	346.6	740.2	310.8	417.9
Financial net	-48.8	-49.0	-46.9	-49.5	-49.4	-55.4	-47.1	-49.2	-53.6
Profit before tax	358.0	255.8	633.6	312.9	304.2	291.2	693.1	261.6	364.3
Taxes	-92.0	-61.0	-170.4	-87.6	-85.2	-81.5	-197.4	-70.6	-98.4
Profit after tax	266.0	194.8	463.2	225.3	219.0	209.7	495.7	191.0	265.9

Balance sheet

Assets SEK million	**2006 31 June**	2005 31 June	2005 31 Dec
Intangible fixed assets	**5,443.8**	5,338.6	5,530.3
Tangible fixed assets	**1,358.5**	1,513.7	1,497.8
Financial assets	**729.1**	614.4	649.8
Stock-in-trade	**2,309.7**	2,322.6	2,156.6
Current receivables	**3,524.4**	3,386.5	4,015.2
Cash and cash equivalents	**942.4**	658.2	683.6
Total assets	**14,307.9**	13,834.0	14,533.3
Shareholders' equity & Liabilities			
Shareholders' equity	**5,372.0**	4,570.5	5,381.3
Provisions for pensions, interest-bearing	**1,660.4**	1,576.3	1,690.4
Long-term liabilities	**4,382.1**	4,728.2	4,468.8
Current liabilities	**2,893.4**	2,959.0	2,992.8
Total Equity & Liabilities	**14,307.9**	13,834.0	14,533.3

Cash flow statement

SEK million	**2006 Q 2**	2005 Q 2	**2006 6 Mon**	2005 6 Mon	2005 FY
Current activities					
Operating profit	**417.9**	353.6	**728.7**	716.0	1,802.8
Adjustment for items not included in cash flow	**70.5**	79.4	**157.9**	154.3	329.1
Financial items	**-53.6**	-49.4	**-102.8**	-98.9	-196.5
Taxes paid	**-111.0**	-131.7	**-242.1**	-236.6	-475.9
Cash flow before changes in working capital	**323.8**	251.9	**541.7**	534.8	1,459.5
Changes in working capital					
Stock-in-trade	**-51.9**	-74.4	**-245.4**	-320.6	-130.4
Rental equipment	**-2.5**	-6.9	**1.1**	-12.3	-13.7
Current receivables	**182.6**	205.3	**449.5**	467.4	-125.7
Current operating liabilities	**62.4**	43.5	**190.2**	-94.3	3.7
Restructuring reserves, utilised	**-0.1**	-0.9	**-0.2**	-20.7	-24.1
Cash flow from operations	**514.3**	418.5	**936.9**	554.3	1,169.3
Investments					
Acquisition of subsidiaries	**8.1**	-125.7	**3.7**	-126.4	-265.4
Net investments in intangible fixed assets	**-51.0**	-43.6	**-83.7**	-72.5	-166.9
Net investments in tangible fixed assets	**-57.3**	-58.1	**-116.6**	-106.4	-224.9
Cash flow from investments	**-100.2**	-227.4	**-196.6**	-305.3	-657.2
Financial activities					
Change in interest-bearing debt	**174.6**	245.5	**-146.7**	390.5	142.6
Change in long-term receivables	**-2.6**	-10.2	**-27.2**	108.5	108.2
Dividend paid	**-403.7**	-333.1	**-403.7**	-333.1	-333.1
Cash flow from financial activities	**-231.7**	-97.8	**-577.6**	165.9	-82.3
Cash flow for the period	**182.4**	93.3	**162.7**	414.9	429.8
Cash and cash equivalents at begin of the year	**688.9**	714.6	**683.6**	484.9	484.9
Translation differences	**71.1**	-149.7	**96.1**	-241.6	-231.1
Cash and cash equivalents at end of the period	**942.4**	658.2	**942.4**	658.2	683.6

Operating cash flow statement

SEK million	**2006 Q 2**	2005 Q 2	**2006 6 Mon**	2005 6 Mon	2005 FY
Business activities					
Operating profit	**417.9**	353.6	**728.7**	716.0	1,802.8
Adjustment for items not included in cash flow	**70.5**	79.4	**157.9**	154.3	329.1
	488.4	433.0	**886.6**	870.3	2,131.9
Changes in operating capital					
Stock-in-trade	**-51.9**	-74.4	**-245.4**	-320.6	-130.4
Rental equipment	**-2.5**	-6.9	**1.1**	-12.3	-13.7
Current receivables	**182.6**	205.3	**449.5**	467.4	-125.7
Current liabilities	**62.4**	43.5	**190.2**	-94.3	3.7
Operating cash flow	**679.0**	600.5	**1,282.0**	910.5	1,865.8

Net interest-bearing debt

SEK million	**2006 31 June**	2005 31 June	2005 31 Dec
Debt to credit institutions	**3,939.5**	4,366.5	4,097.4
Provisions for pensions, interest-bearing	**1,660.4**	1,576.3	1,690.4
Less liquid funds	**-942.4**	-658.2	-683.6
Net interest-bearing debt	**4,657.5**	5,284.6	5,104.2

Changes to shareholders' equity

SEK million	**2006 31 June**	2005 31 June	2005 31 Dec
Shareholders' equity – opening balance	**5,381.3**	4,269.6	4,269.6
Effect of adopting to IFRS on opening balance		97.0	97.0
Shareholders' equity - opening balance according to new principle	**5,381.3**	4,366.6	4,366.6
Dividend distributed	**-403.7**	-333.1	-333.1
Change of reserve hedge accounting	**134.6**	-251.3	-184.5
Translation differences	**-197.1**	344.0	382.6
Net profit	**456.9**	444.3	1,149.7
Shareholders' equity – closing balance	**5,372.0**	4,570.5	5,381.3
Attributable to:			
Parent company's shareholders	**5,296.5**	4,505.0	5,307.4
Minority interest	**75.5**	65.5	73.9
Total shareholders' equity	**5,372.0**	**4,570.5**	**5,381.3**

Key figures

	2006 Q 2	2005 Q 2	Change	2006 6 Mon	2005 6 Mon	Change	2005 FY
Orders received, SEK million	**3,355.1**	2,883.3	*16.4%*	**6,668.8**	5,766.8	*15.6%*	12,225.0
adjusted for currency flucs.& corp.acqs			*13.0%*			*8.3%*	
Net sales, SEK million	**3,147.7**	2,739.0	*14.9%*	**6,122.5**	5,264.2	*16.3%*	11,880.4
adjusted for currency flucs.& corp.acqs			*10.3%*			*8.8%*	
Earnings per share after full tax, SEK	**1.31**	1.08	*21.4%*	**2.24**	2.16	*3.5%*	5.64
Nmb of shares, thousands	**201,874**	201,874		**201,874**	201,874		201,874
Operating capital, SEK million				**10,041.5**	8,740.3	*14.9%*	9,571.0
Return on operating capital, per cent				**17.9%**	18.9%	*-1.0%*	18.5%
Return on equity, per cent				**22.6%**	26.1%	*-3.5%*	24.3%
Net debt/equity ratio, multiple				**0.87**	1.16	*-0.29*	0.95
Interest cover, multiple				**8.5**	7.9	*0.6*	8.3
Equity/assets ratio, per cent				**37.5%**	33.0%	*4.5%*	37.0%
Net investments in tangible fixed assets, SEK million				**116.6**	106.4		224.9
Number of employees at the period's end				**7,382**	7,201		7,362

Definitions

EBIT Operating profit

EBITA Operating profit before amortsation of intangible fixed assets identified upon business acquisitions.